Thermo Fisher Scientific Inc. (TMO) stock
TMONYSEMeasuring & Controlling Devices, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Oct 30, 2026Score 12/3027% above fair value
$697.00−12.18 (-1.72%)
Close on Oct 30, 2026Market cap $257.71BP/E 36.8Yield 0.25%
Earnings
Thermo Fisher Scientific's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Jan 28, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$12.14B
+9.2% on a year earlier
adjusted EPS, Q3 FY2026
$6.68
$5.79 a year earlier
Latest guidance
Raised
Oct 23, 2024 · 2 items
Quarterly results
Revenue and earnings per share from each of Thermo Fisher Scientific's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Jan 28, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 27, 2026 | Oct 21, 2026before the open | $12.14B | +9.2% | $4.64 | $6.68 | Release |
| Q2 FY2026ended Jun 27, 2026 | Jul 23, 2026before the open | $11.99B | +10.5% | $4.68 | $6.03 | Release |
| Q1 FY2026ended Mar 28, 2026 | Apr 23, 2026before the open | $11.01B | +6.3% | $4.43 | $5.44 | Release |
| Q4 FY2025ended Dec 31, 2025 | Jan 29, 2026before the open | $12.21B | +7.1% | $5.21 | $6.57 | Release |
| Q3 FY2025ended Sep 27, 2025 | Oct 22, 2025before the open | $11.12B | +4.9% | $4.27 | $5.79 | Release |
| Q2 FY2025ended Jun 28, 2025 | Jul 23, 2025before the open | $10.85B | +2.9% | $4.28 | $5.36 | Release |
| Q1 FY2025ended Mar 29, 2025 | Apr 23, 2025before the open | $10.36B | +0.2% | $3.98 | $5.15 | Release |
| Q4 FY2024ended Dec 31, 2024 | Jan 30, 2025before the open | $11.40B | +4.7% | $4.78 | $6.10 | Release |
| Q3 FY2024ended Sep 28, 2024 | Oct 23, 2024before the open | $10.60B | +0.3% | $4.25 | $5.28 | Release |
| Q2 FY2024ended Jun 29, 2024 | Jul 24, 2024before the open | $10.54B | -1.4% | $4.04 | $5.37 | Release |
| Q1 FY2024ended Mar 30, 2024 | Apr 24, 2024before the open | $10.34B | -3.5% | $3.46 | $5.11 | Release |
| Q4 FY2023ended Dec 31, 2023 | Jan 31, 2024before the open | $10.89B | -4.9% | $4.20 | $5.67 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 25, 2023before the open | $10.57B | -1.0% | $4.42 | $5.69 | Release |
| Q2 FY2023ended Jul 1, 2023 | Jul 26, 2023before the open | $10.69B | -2.6% | $3.51 | $5.15 | Release |
| Q1 FY2023ended Apr 1, 2023 | Apr 26, 2023before the open | $10.71B | -9.4% | $3.32 | $5.03 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 1, 2023before the open | $11.45B | +7.0% | $4.01 | $5.40 | Release |
| Q3 FY2022ended Oct 1, 2022 | Oct 26, 2022before the open | $10.68B | +14.5% | $3.79 | $5.08 | Release |
| Q2 FY2022ended Jul 2, 2022 | Jul 28, 2022before the open | $10.97B | – | $4.22 | $5.51 | Release |
| Q1 FY2022ended Apr 2, 2022 | Apr 28, 2022before the open | $11.82B | – | $5.61 | $7.25 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 2, 2022before the open | $10.70B | – | $4.17 | $6.54 | Release |
| Q3 FY2021ended Oct 2, 2021 | Oct 27, 2021before the open | $9.33B | – | $4.79 | $5.76 | Release |
| Q2 FY2021ended Jul 3, 2021 | Jul 28, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Apr 3, 2021 | Apr 29, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 1, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 26, 2020 | Oct 21, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Thermo Fisher Scientific guided for has been reported
Guidance history
Every forecast Thermo Fisher Scientific put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 23, 2024 | adjusted EPS | FY2024 | $21.35 – $22.07 | Raised |
| Oct 23, 2024 | Revenue | FY2024 | $42.40B – $43.30B | Reaffirmed |
| Jul 24, 2024 | adjusted EPS | FY2024 | $21.29 – $22.07 | Raised |
| Jul 24, 2024 | revenue | FY2024 | $42.40B – $43.30B | Raised |
| Apr 24, 2024 | adjusted EPS | FY2024 | $21.14 – $22.02 | Raised |
| Apr 24, 2024 | revenue | FY2024 | $42.30B – $43.30B | Raised |
| Jan 31, 2024 | adjusted EPS | FY2024 | $20.95 – $22.00 | New |
| Jan 31, 2024 | revenue | FY2024 | $42.10B – $43.30B | New |
| Oct 25, 2023 | adjusted EPS | FY2023 | $21.50 | Lowered |
| Oct 25, 2023 | Core organic revenue growth | FY2023 | +1% | Lowered |
| Oct 25, 2023 | revenue | FY2023 | $42.70B | Lowered |
| Jul 26, 2023 | adjusted EPS | FY2023 | $22.28 – $22.72 | Lowered |
| Jul 26, 2023 | Core organic revenue growth | FY2023 | +2% – +4% | Lowered |
| Jul 26, 2023 | revenue | FY2023 | $43.40B – $44.00B | New |
| Feb 1, 2023 | adjusted EPS | FY2023 | $23.70 | New |
| Feb 1, 2023 | Core organic revenue growth | FY2023 | +7% | New |
| Feb 1, 2023 | revenue | FY2023 | $45.30B | New |
| Oct 27, 2021 | adjusted EPS | FY2021 | $23.37 | New |
| Oct 27, 2021 | revenue | FY2021 | $37.10B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Thermo Fisher Scientific filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- News
- Results
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results